Abstract
The respiratory formulary prescription cost (net ingredient) accounts for around 12% of the total cost of all prescriptions of £8.82 billion in England. In the current climate it is essential to ensure that medication is prescribed appropriately so that patients benefit from their medication and are not prescribed medication that is unlikely to benefit them, thereby reducing medicines waste. Asthma and chronic obstructive pulmonary disease (COPD) are two areas of respiratory disease that affect significant numbers of the population (5.4 million and 1.2 million people in the UK respectively). Strategies to improve medicines optimisation in respiratory disease can potentially have huge implications both in terms of improving quality of life for patients and costs. Medicines optimisation is defined as ‘a person-centred approach to safe and effective medicines use to ensure people obtain the best possible outcomes from their medicines’. It is clear with the prevalence of respiratory disease and its significant impact on the healthcare budget through prescribing that medicines optimisation is an essential consideration for those commissioning and responsible for designing services.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
